Table 4.
Post-baseline genotypic analysis through Week 48 in the 15 patients in the resistance analysis population
| Patient number | N[t]RTI backbone | Treatment cohort | Visit (week) | RAMs emerging* | |
|---|---|---|---|---|---|
| Protease | Reverse transcriptase | ||||
| 1 | Abacavir plus tenofovir | Naïve | 24 | None | None |
| 2 | Emtricitabine/tenofovir | Naïve | 12 | None | None |
| 3 | Emtricitabine/tenofovir | Naïve | 48 | I93I/L | I142L/P |
| 4 | Emtricitabine/tenofovir | Experienced | 24 | None | K22K/R |
| 5 | Emtricitabine/tenofovir | Naïve | 36 | R57R/K | M184V |
| 6 | Emtricitabine/tenofovir | Naïve | 16 | V32V/A, P39P/S | K122K/E, D123D/G/N/S, D177D/G, I178M |
| 7 | Emtricitabine/tenofovir | Naïve | 48 | None | D123D/E |
| 8 | Emtricitabine/tenofovir | Experienced | 48 | None | K122K/E, A272A/P |
| 9 | Emtricitabine/tenofovir | Experienced | 12 | I84I/V | E138T, T165A/E, R211R/K |
| 10 | Emtricitabine/tenofovir | Naïve | 8 | G86G/E | D123N |
| 11 | Emtricitabine/tenofovir plus zidovudine | Experienced | 48 | None | I195I/L |
| 12 | Abacavir plus tenofovir | Experienced | 36 | R41R/K | None |
| 13 | Emtricitabine/tenofovir | Naïve | 48 | V77V/I | E6E/K, E224E/Q, V245Q, T286T/A, V292V/I |
| 14 | Emtricitabine/tenofovir plus zidovudine | Experienced | 48 | None | E6E/D, V60I |
| 15 | Emtricitabine/tenofovir | Experienced | 36 | None | M184V |
*Compared to screening genotype – emerging primary resistance-associated mutations (RAMs) are shown in bold; N[t]RTI nucleoside/tide reverse transcriptase inhibitor.